Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (noted as Chemomab Therapeutics Ltd. in metadata) covers the month of May 2019. The registrant is a foreign private issuer based in Jerusalem, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural announcement regarding corporate governance rather than a financial results report.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this document.
Guidance, Outlook, and Corporate Actions
The primary purpose of this filing is to announce the 2019 Annual General Meeting of Shareholders. Key details include:
- Date and Time: Tuesday, July 2, 2019, at 4:00 p.m. (Israel time).
- Location: Executive offices at 1/3 High-Tech Village, Givat Ram, Jerusalem, Israel.
- Documentation: The company will distribute a proxy statement, proposed resolutions, and proxy cards to shareholders of record.
- Exhibits: The filing includes the Notice of the Meeting (Exhibit 99.1), Proxy Statement (Exhibit 99.2), and Proxy Card (Exhibit 99.3).
Investor Verification Checklist
- Verify the record date for the Annual General Meeting to confirm shareholder eligibility.
- Review the attached Proxy Statement (Exhibit 99.2) for specific resolutions to be voted upon.
- Confirm the company's current name status, as the metadata lists "Chemomab Therapeutics Ltd." while the filing text identifies "Anchiano Therapeutics Ltd."
- Check subsequent filings for the actual financial results, as none are included in this 6-K.